WO2002047611A8 - Cddo-compounds and combination therapies thereof - Google Patents

Cddo-compounds and combination therapies thereof

Info

Publication number
WO2002047611A8
WO2002047611A8 PCT/US2001/044541 US0144541W WO0247611A8 WO 2002047611 A8 WO2002047611 A8 WO 2002047611A8 US 0144541 W US0144541 W US 0144541W WO 0247611 A8 WO0247611 A8 WO 0247611A8
Authority
WO
WIPO (PCT)
Prior art keywords
cddo
compounds
combination therapies
combination
chemotherapeutic agents
Prior art date
Application number
PCT/US2001/044541
Other languages
French (fr)
Other versions
WO2002047611A2 (en
WO2002047611A3 (en
Inventor
Marina Konopleva
Michael Andreef
Michael Sporn
Original Assignee
Univ Texas
Marina Konopleva
Michael Andreef
Michael Sporn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Marina Konopleva, Michael Andreef, Michael Sporn filed Critical Univ Texas
Priority to EP01989130A priority Critical patent/EP1395255A4/en
Priority to AU2002243246A priority patent/AU2002243246A1/en
Priority to CA002430454A priority patent/CA2430454A1/en
Publication of WO2002047611A2 publication Critical patent/WO2002047611A2/en
Publication of WO2002047611A8 publication Critical patent/WO2002047611A8/en
Publication of WO2002047611A3 publication Critical patent/WO2002047611A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided, Also provided are methods to treat graft versus host diseases using the CDDO compounds.
PCT/US2001/044541 2000-11-28 2001-11-28 Cddo-compounds and combination therapies thereof WO2002047611A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01989130A EP1395255A4 (en) 2000-11-28 2001-11-28 Cddo-compounds and combination therapies thereof
AU2002243246A AU2002243246A1 (en) 2000-11-28 2001-11-28 Cddo-compounds and combination therapies thereof
CA002430454A CA2430454A1 (en) 2000-11-28 2001-11-28 Cddo-compounds and combination therapies thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25367300P 2000-11-28 2000-11-28
US60/253,673 2000-11-28

Publications (3)

Publication Number Publication Date
WO2002047611A2 WO2002047611A2 (en) 2002-06-20
WO2002047611A8 true WO2002047611A8 (en) 2003-06-26
WO2002047611A3 WO2002047611A3 (en) 2003-12-24

Family

ID=22961235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044541 WO2002047611A2 (en) 2000-11-28 2001-11-28 Cddo-compounds and combination therapies thereof

Country Status (4)

Country Link
EP (1) EP1395255A4 (en)
AU (1) AU2002243246A1 (en)
CA (1) CA2430454A1 (en)
WO (1) WO2002047611A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45288E1 (en) 2008-04-18 2014-12-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US9102681B2 (en) 2008-04-18 2015-08-11 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US9174941B2 (en) 2010-12-17 2015-11-03 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US9233998B2 (en) 2008-04-18 2016-01-12 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
US9249089B2 (en) 2008-04-18 2016-02-02 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2472581C (en) 2002-01-15 2012-06-26 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
CN108434151A (en) 2008-01-11 2018-08-24 里亚塔医药公司 Synthesize triterpene compound and the method to cure the disease
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
JP5758801B2 (en) 2008-07-22 2015-08-05 トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ Monocyclic cyanoenone and description of how to use it
ME03713B (en) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoxolone methyl for the treatment of obesity
LT2683731T (en) 2011-03-11 2019-07-10 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
ES2861393T3 (en) 2012-04-27 2021-10-06 Reata Pharmaceuticals Inc 2,2-Difluoropropionamide derivatives of methyl bardoxolone, pharmaceutical compositions and polymorphs thereof for use in the treatment of certain conditions
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
PL2892912T3 (en) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
TWI649330B (en) 2013-04-24 2019-02-01 艾伯維有限公司 2,2-difluoropropionamide derivative of methyl bardoxolone, polymorph thereof and use thereof
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
WO2016033132A1 (en) 2014-08-26 2016-03-03 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
KR102686868B1 (en) 2015-02-12 2024-07-19 리아타 파마슈티컬즈, 아이엔씨. Imidazolyl tricyclic enone as an antioxidant inflammation regulator
NZ741082A (en) 2015-09-23 2023-06-30 Reata Pharmaceuticals Inc C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
CA3042123A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (en) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
KR20210032936A (en) 2018-06-15 2021-03-25 리아타 파마슈티컬즈, 아이엔씨. Pyrazole and imidazole compounds for inhibition of IL-17 and ROR gamma
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
US20220133748A1 (en) * 2019-02-15 2022-05-05 Triterpenoid Therapeutics, Inc. Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease
CN114949230A (en) * 2022-06-13 2022-08-30 厦门大学附属第一医院 Combined pharmaceutical composition for preventing and/or treating acute myeloid leukemia and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45288E1 (en) 2008-04-18 2014-12-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
USRE45325E1 (en) 2008-04-18 2015-01-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US9102681B2 (en) 2008-04-18 2015-08-11 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US9233998B2 (en) 2008-04-18 2016-01-12 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
US9249089B2 (en) 2008-04-18 2016-02-02 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US9174941B2 (en) 2010-12-17 2015-11-03 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof

Also Published As

Publication number Publication date
CA2430454A1 (en) 2002-06-20
EP1395255A4 (en) 2007-09-12
EP1395255A2 (en) 2004-03-10
AU2002243246A1 (en) 2002-06-24
WO2002047611A2 (en) 2002-06-20
WO2002047611A3 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
WO2002047611A3 (en) Cddo-compounds and combination therapies thereof
WO2006015263A3 (en) Lonidamine analogs
AU2001247715A1 (en) Methods to control the droop when powering dual mode processors and associated circuits
AU2001288432A1 (en) Materials and methods to potentiate cancer treatment
HK1037981A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C.
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
WO2007008200A8 (en) Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
AU2001286727A1 (en) Prodrugs activated by plasmin and their use in cancer chemotherapy
EP1471871A4 (en) Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
MX259137B (en) Mixed zeaxanthin ester concentrate and uses thereof.
MXPA05013667A (en) Dual component skin care compositions that comprise a self-tanning agent.
AU2002303681A1 (en) Liposuction cannula with abrading apertures
WO2004012662A3 (en) Improved treatment of cancer with glutamine
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
AU2158601A (en) Antiviral agent for use in treatment of cancer
WO2004080421A3 (en) Improved antitumoral treatments
MXPA03003011A (en) Methods of inducing cancer cell death and tumor regression.
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
WO2000013712A3 (en) Methods and compositions for the prevention or treatment of cancer
AU2001261750A1 (en) Laminate and its use
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
WO2006071955A3 (en) Glufosfamide combination therapy
CA97550S (en) Golf bag

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001989130

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2430454

Country of ref document: CA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 25/2002 UNDER (71) THE NAME SHOULD READ "BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001989130

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP